Special Issue

Myodegeneration

Message from the Guest Editors

Myodegeneration is a controversial and poorly defined designation that rarely appears in textbooks and publications. Mainly introduced in the context of inclusion body myositis (IBM), the term refers to a pathogenesis or pathological alteration in skeletal muscle, similar to that described for neurodegeneration in the central nervous system. Key to the concept of "classical" neurodegeneration is the progressive loss of neurons, which represents a significant difference between these two tissues. Muscle fibers, unlike neurons, are capable of regeneration. Myodegeneration is therefore best understood in the earlier investigations of V. Askanas and W.K. Engel, who compared the pathological findings in IBM with those of Alzheimer disease. In this sense, myodegeneration could be regarded as the accumulation of pathological protein aggregates. This broader interpretation applies to IBM and hereditary inclusion body myopathies.

This Special Issue aims to summarize the cardinal aspects of myodegeneration, including a systematic comparison of the diseases with protein aggregates in skeletal muscle.

Guest Editors

Dr. Regina R. Reimann
Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland

Prof. Dr. Elisabeth Rushing
1. Institute of Pathology, Cantonal Hospital, Luzern, Switzerland
2. MEDICA Medical Laboratories, Zurich, Switzerland

Deadline for manuscript submissions

closed (31 May 2023)

Muscles

an Open Access Journal by MDPI

Indexed in PubMed
Tracked for Impact Factor

mdpi.com/si/142487

Muscles
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
muscles@mdpi.com

mdpi.com/journal/muscles

Muscles

an Open Access Journal by MDPI

Indexed in PubMed
Tracked for Impact Factor

mdpi.com/journal/muscles

About the Journal

Message from the Editor-in-Chief

Muscles is a publishing platform that promotes discoveries related to the realm of neuromuscular disorders (genetic and acquired neuromuscular disorders in man) and relevant cell and animal models. The journal aims to be a publishing venue that disseminates scientific papers with emphasis on multidisciplinary approaches to understand the complexities and interactions occurring on a variety of metabolic, endocrinological and neurogenic disorders. Papers on sarcopenia, exercise and atrophy/hypertrophy of muscles will be given space and attention, as will clinical trials and possible pharmacological interventions. A rapid turnaround time and full open access provide the opportunity to make research results immediately available to scientific communities and the general public.

Editor-in-Chief

Prof. Dr. Corrado Angelini
Department of Neurosciences, University of Padova, 35128 Padova, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), Scopus and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.9 days after submission; acceptance to publication is undertaken in 3.7 days (median values for papers published in this journal in the first half of 2025).

MDPI